口服四氢尿苷联合地西他滨用于镰状细胞病非细胞毒性表观遗传基因调控:一项随机1期研究
这项首次人体随机1期试验在镰状细胞病成人中评估口服四氢尿苷(THU)联合地西他滨抑制DNA甲基转移酶1(DNMT1)以再诱导胎儿血红蛋白(HbF)。主要终点≥3级非血液学毒性未触发,不良事件与安慰剂组无显著差异;地西他滨0.16 mg/kg使HbF升高4%-9%(P<0.001),总血红蛋白增加1.2-1.9 g/dL(P=0.01)。
要点
- 口服THU 10 mg/kg后地西他滨剂量递增至0.16 mg/kg,未触发≥3级非血液学毒性主要终点。
- 地西他滨0.16 mg/kg使外周血单核细胞DNMT1蛋白降低>75%,HbF升高4%-9%(P<0.001)。
- 该剂量下总血红蛋白增加1.2-1.9 g/dL(P=0.01),同时网织红细胞下降。
核心结论
- 在本研究中,口服THU-地西他滨用于镰状细胞病患者是安全的,并通过靶向DNMT1上调红细胞中的HbF。
- 进一步研究应探讨临床获益及迄今未发现的潜在危害。
研究设计与样本
- 首次人体随机1期临床试验(NCT01685515),联合地西他滨耗竭DNMT1与THU抑制胞苷脱氨酶(CDA)。
- 口服THU 10 mg/kg后给予口服地西他滨,剂量从0.01、0.02、0.04、0.08或0.16 mg/kg递增,以确定耗竭DNMT1而无细胞毒性的最小活性剂量。
- 患者为尽管接受标准治疗仍面临早死风险的镰状细胞病成人,按3:2随机分配至THU-地西他滨组或安慰剂组,共5个队列、每队列5例患者,每周治疗2次、持续8周,随访4周。
主要发现
- 主要终点≥3级非血液学毒性未触发,THU-地西他滨组与安慰剂组的不良事件无显著差异。
- 地西他滨0.16 mg/kg剂量下,血浆浓度峰值约50 nM(Cmax),并持续升高数小时。
- 该剂量使外周血单核细胞DNMT1蛋白降低>75%,重复元件CpG甲基化降低约10%,HbF升高4%-9%(P<0.001),使富集胎儿血红蛋白的红细胞(F细胞)加倍至约占总红细胞的80%。
- 总血红蛋白增加1.2-1.9 g/dL(P=0.01),同时网织红细胞下降;溶血、血栓形成倾向和炎症生物标志物(LDH、胆红素、D-二聚体、C反应蛋白[CRP])改善。
- 如非细胞毒性DNMT1耗竭所预期,血小板增加而中性粒细胞同时减少,但未达到需要暂停治疗的程度。
关键数值与推荐
- 主要终点为≥3级非血液学毒性。
- 口服THU剂量为10 mg/kg,地西他滨剂量递增水平为0.01、0.02、0.04、0.08或0.16 mg/kg。
- 地西他滨0.16 mg/kg时Cmax约50 nM,DNMT1蛋白降低>75%,重复元件CpG甲基化降低约10%,HbF升高4%-9%(P<0.001),F细胞增至约占总红细胞80%,总血红蛋白增加1.2-1.9 g/dL(P=0.01)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作为早期阶段研究,局限性包括每个剂量水平的患者数量少。
- 评估临床获益的能力有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sickle cell disease (SCD), a congenital hemolytic anemia that exacts terrible global morbidity and mortality, is driven by polymerization of mutated sickle hemoglobin (HbS) in red blood cells (RBCs). Fetal hemoglobin (HbF) interferes with this polymerization, but HbF is epigenetically silenced from infancy onward by DNA methyltransferase 1 (DNMT1). METHODS AND FINDINGS: To pharmacologically re-induce HbF by DNMT1 inhibition, this first-in-human clinical trial (NCT01685515) combined 2 small molecules-decitabine to deplete DNMT1 and tetrahydrouridine (THU) to inhibit cytidine deaminase (CDA), the enzyme that otherwise rapidly deaminates/inactivates decitabine, severely limiting its half-life, tissue distribution, and oral bioavailability. Oral decitabine doses, administered after oral THU 10 mg/kg, were escalated from a very low starting level (0.01, 0.02, 0.04, 0.08, or 0.16 mg/kg) to identify minimal doses active in depleting DNMT1 without cytotoxicity. Patients were SCD adults at risk of early death despite standard-of-care, randomized 3:2 to THU-decitabine versus placebo in 5 cohorts of 5 patients treated 2X/week for 8 weeks, with 4 weeks of follow-up. The primary endpoint was ≥ grade 3 non-hematologic toxicity. This endpoint was not triggered, and adverse events (AEs) were not significantly different in THU-decitabine-versus placebo-treated patients. At the decitabine 0.16 mg/kg dose, plasma concentrations peaked at approximately 50 nM (Cmax) and remained elevated for several hours. This dose decreased DNMT1 protein in peripheral blood mononuclear cells by >75% and repetitive element CpG methylation by approximately 10%, and increased HbF by 4%-9% (P < 0.001), doubling fetal hemoglobin-enriched red blood cells (F-cells) up to approximately 80% of total RBCs. Total hemoglobin increased by 1.2-1.9 g/dL (P = 0.01) as reticulocytes simultaneously decreased; that is, better quality and efficiency of HbF-enriched erythropoiesis elevated hemoglobin using fewer reticulocytes. Also indicating better RBC quality, biomarkers of hemolysis, thrombophilia, and inflammation (LDH, bilirubin, D-dimer, C-reactive protein [CRP]) improved. As expected with non-cytotoxic DNMT1-depletion, platelets increased and neutrophils concurrently decreased, but not to an extent requiring treatment holds. As an early phase study, limitations include small patient numbers at each dose level and narrow capacity to evaluate clinical benefits. CONCLUSION: Administration of oral THU-decitabine to patients with SCD was safe in this study and, by targeting DNMT1, upregulated HbF in RBCs. Further studies should investigate clinical benefits and potential harms not identified to date. TRIAL REGISTRATION: ClinicalTrials.gov, NCT01685515.
引用
- Molokie R, Lavelle D, Gowhari M, et al. Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study. PLoS Med. 2017. PMID: 28880867. doi:10.1371/journal.pmed.1002382
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。